Ngôn ngữ sử dụng
Cách trích dẫn
Tải xuống
Tóm tắt
Objective: To describe the treatment adherence of outpatients with chronic myeloid leukemia at national institute of hematology & blood transfusion.
Subjects and Methods: A cross-sectional descriptive study was conducted on 170 outpatients at National Institute of Hematology and Blood Transfusion from January 2022 to June 2022.
Results: 98.8% of patients came to the clinic for examination on time. The percentage of patients with drug adherence accounted for 68.8%. There were still many patients who did not comply because they forgot to take the medicine, stopped taking it on their own, and found it difficult to take the medicine. 42.35% of patients had limited knowledge about the disease. Adherence to the diet was relatively good. However, the salt and fat reduction diet was still not well implemented. The exercise regime was still limited, the percentage of people who do exercise occasionally and do not exercise accounted for 50.6%.
Conclusion: The rate of patient adherence to treatment was still not high. Interventions are needed to enhance the drug adherence of patients.
Từ khóa
Tài liệu tham khảo
Hoang Quoc H, Trinh Thi X, Pham Quang H, Tran Cong H, Vu Thi Bich H, Le Q T, et al. Applied bioinformatics study to determine genetic variation in patients with chronic myeloid leukemia. Vietnam Science and Technology Magazine. 2017;3:22-6.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. acs journals 2016;66(1):7-30. https://doi.org/10.3322/caac.21332
Mehta R, Tsilimigras DI, Paredes AZ, Hyer M, Dillhoff M, Cloyd JM, et al. County-Level Variation in Utilization of Surgical Resection for Early-Stage Hepatopancreatic Cancer Among Medicare Beneficiaries in the USA. Journal of Gastrointestinal Surgery. 2021;25(7):1736-44. doi: 10.1007/s11605-020-04778-1
Khanh NB. Research on the treatment of leukemia by stem cell transplantation from community cord blood banks at the National Institute of Hematology and Blood Transfusion. [Thesis of Doctor of Medicine at Hanoi Medical University] 2021.
Efficace F, Rosti G, Cottone F, Breccia M, Castagnetti F, Iurlo A, et al. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leukemia Research. 2014;38(3):294-8. doi: 10.1016/j.leukres.2013.07.003.
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England journal of medicine. 2006;355(23):2408-17. doi: 10.1056/NEJMoa062867.
Jönsson S, Olsson B, Söderberg J, Wadenvik H. Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study. Annals of Hematology. 2012;91(5):679-85. doi: 10.1007/s00277-011-1359-0
Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087.
Brown SA, Grimes DE. A meta-analysis of nurse practitioners and nurse midwives in primary care. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]: Center for Reviews and Dissemination (UK); 1995.
Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35(5):626-30. doi: 10.1016/j.leukres.2010.10.017.
Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA: a cancer journal for clinicians. CA Cancer J Clin, 2009;59(1):56-66. doi: 10.3322/caac.20004.
Breccia M, Efficace F, Alimena G. Imatinib treatment in chronic myelogenous leukemia: What have we learned so far? Cancer letters. 2011;300(2):115-21. doi: 10.1016/j.canlet.2010.10.018.
Morisky DE, Ang A, Krousel - Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. The journal of clinical hypertension. 2008;10(5):348-54. doi: 10.1111/j.1751-7176.2008.07572.x.
Tsai YF, Huang WC, Cho SF, Hsiao HH, Liu YC, Lin SF, et al. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan. Medicine. 2018;97(26). doi: 10.1097/MD.0000000000011322.
Loan NT, Linh NTN, Mai NN, Trang PT, Anh CV, Hong VT. Current status of treatment adherence and some related factors in HCC patients undergoing outpatient treatment at 108 Military Central Hospital in 2021. Journal of clinical medicine. 2022;17(8):137-44.
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại 4.0 International Giấy phép .
Bản quyền (c) 2023 Tạp chí Khoa học Điều dưỡng